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A B S T R A C T
Neurodegenerative and neuromuscular disorders can manifest throughout the lifespan of an individual, from
infant to elderly individuals. Axonal and synaptic degeneration are early and critical elements of nearly all
human neurodegenerative diseases and neural injury, however the molecular mechanisms which regulate this
process are yet to be fully elucidated. Furthermore, how the molecular mechanisms governing degeneration are
impacted by the age of the individual is poorly understood. Interestingly, in mice which are under 3 weeks of
age, the degeneration of axons and synapses following hypoxic or traumatic injury is signiﬁcantly slower. This
process, known as Wallerian degeneration (WD), is a molecularly and morphologically distinct subtype of
neurodegeneration by which axons and synapses undergo distinct fragmentation and death following a range of
stimuli. In this study, we ﬁrst use an ex-vivo model of axon injury to conﬁrm the signiﬁcant delay in WD in
neonatal mice. We apply tandem mass-tagging quantitative proteomics to proﬁle both nerve and muscle between
P12 and P24 inclusive. Application of unbiased in silico workﬂows to relevant protein identiﬁcations highlights a
steady elevation in oxidative phosphorylation cascades corresponding to the accelerated degeneration rate. We
demonstrate that inhibition of Complex I prevents the axotomy-induced rise in reactive oxygen species and
protects axons following injury. Furthermore, we reveal that pharmacological activation of oxidative phos-
phorylation signiﬁcantly accelerates degeneration at the neuromuscular junction in neonatal mice. In summary,
we reveal dramatic changes in the neuromuscular proteome during post-natal maturation of the neuromuscular
system, and demonstrate that endogenous dynamics in mitochondrial bioenergetics during this time window
have a functional impact upon regulating the stability of the neuromuscular system.
1. Introduction
Throughout the lifespan of an individual, neurons are susceptible to
degeneration in heritable and spontaneous disease, and following a
wide variety of insults, including chemical damage and physical
trauma. Neurodegenerative disorders are a primary cause of death in
adult and elderly populations, and although speciﬁc neurodegenerative
disorders in children are considered rare, collectively they have been
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estimated to account for 28% of admissions to pediatric neurology
wards(de Pedro-Cuesta et al., 2015; Dyken and Krawiecki, 1983).
Neurodegeneration caused by both pathological and traumatic insult
are united by a common vulnerability of the axonal and synaptic
compartments of the cell. Although axonal and synaptic degeneration
appears to be mechanistically distinct from somatic degeneration, the
molecular mechanisms which regulate the vulnerability of the axonal
and synaptic compartments of the neuron, and the process by which
they degenerate are yet to be fully elucidated. Furthermore, how the
molecular mechanisms governing degeneration are impacted by the age
of the individual is poorly understood.
Axon and synapses can degenerate in a range of mechanistically
distinct manners(Yaron and Schuldiner, 2016). Wallerian degeneration
(WD) refers to one of these processes, during which axons and their pre-
synaptic terminals undergo rapid fragmentation, degradation and
clearance by scavenging macrophages and Schwann Cells (Saxena and
Caroni, 2007; Catenaccio et al., 2017). This pattern of degeneration is
also observed following trauma to the axon or in diseases that include
multiple sclerosis or stroke (Kawachi and Lassmann, 2017; Stoll and
Muller, 1999; Wang et al., 2012). We have recently described that the
rate of WD following axotomy is signiﬁcantly slower in neonatal mice
compared to adults (Murray et al., 2011). An ex-vivo model of hypoxia-
reperfusion injury using tissue from adult (P28) mice induced degen-
eration of 95% of neuromuscular junctions (NMJs) within 24 h. How-
ever, the same injury in nerve-muscle preparations from neonatal (P2)
mice resulted in loss of motor nerve terminals from only 5% of NMJs. A
similar delay in WD following traumatic nerve injury from axotomy was
observed in mice aged up to P20. Further investigation into this phe-
nomenon revealed that the delay in the rate of injury-induced NMJ
degeneration was progressively lost between P12 and P25. Interest-
ingly, a preconditioning lesion to generate immature NMJs in adult
mice (cf. (Gillingwater et al., 2002)) failed to mitigate this rapid de-
generation response post axotomy in adult mice (Murray et al., 2011). It
therefore appears that the regulatory elements responsible for this
dramatic increase in the rate of WD at the NMJ arise from the sur-
rounding environment, namely the nerve or muscle, rather than the
NMJ itself. Consequently, factors which contribute to the stability and
degeneration axonal and synaptic compartments of the cell are devel-
opmentally regulated. In order to gain insight into the mechanisms
which underlie neurodegeneration, and how they evolve and adapt
during the lifespan of an individual, it is important to understand the
mechanisms which regulate the delay in axon degeneration in neonatal
mice.
While the deﬁnitive mechanisms underpinning WD remain un-
resolved, a number of speciﬁc mutations have been shown to pro-
foundly inﬂuence its rate, and thus serve as compelling tools to study
perturbed WD proﬁles: Perhaps the best known of these mutations
(indeed named for its eﬀect on the process),− Wallerian Degeneration
Slow (Wlds) - in mice delays axonal degeneration by a factor of ten
(Brown et al., 1994; Lyon et al., 1993; Oyebode et al., 2012). This
mutation incorporates an in-frame fusion between genes encoding ni-
cotinamide nucleotide adenylyltransferase 1 (Nmnat1) and the N-ter-
minus of ubiquitination factor E4B (Ube4b) (Coleman et al., 1998;
Conforti et al., 2000; Wishart et al., 2007). Transgenic expression of the
chimeric protein delays axon degeneration following nerve injury in
mice, rats, Drosophila and zebraﬁsh (Adalbert et al., 2005; Hoopfer
et al., 2006; Mack et al., 2001; O'Donnell et al., 2014; Wang et al.,
2001a; Wishart et al., 2012). Axonal protection by WldS protein is also
observed following a range of traumatic, chemical and pathological
insults, in both the central and peripheral nervous systems (Beirowski
et al., 2008; Beirowski et al., 2010; Ferri et al., 2003; Gillingwater et al.,
2004; Howell et al., 2007; Meyer zu Horste et al., 2011; Mi et al., 2005;
Sajadi et al., 2004; Samsam et al., 2003; Wang et al., 2001b, 2002; Zhu
et al., 2014).
Recently, Sterile Alpha and TIR motif-containing 1 (Sarm1) was
identiﬁed as a critical component of the Wallerian Degeneration
pathway. Knockout of Sarm1 in both Drosophila and mice phenocopies
WldS gene expression and protects axons from WD for weeks post ax-
otomy (Osterloh et al., 2012). Studies of WldS and Sarm1, and the
mechanisms by which they exert their protective inﬂuence have not
only enabled the discovery of key molecular players involved in the
degenerative process, but also have cast light upon other factors that
may modulate axonal and synaptic protection. Indeed, work on both
Wlds and Sarm1 suggest mitochondria have an important role in the
progression of WD. This was ﬁrst suggested as a possibility ten years
ago following early proteomic investigations into altered synaptic sta-
bility using Wlds (Wishart et al., 2007). Subsequently, Barrientos et al.,
demonstrated that inhibition of the mitochondrial permeability transi-
tion pore (MPTP) could phenocopy the axon protection observed with
Wlds (Barrientos et al., 2011). More recently Avery et al. demonstrated
that Wlds is indeed likely acting through altered mitochondrial pro-
cesses such as activity, dynamics and buﬀering capacity (Avery et al.,
2012). Although mitochondria have been strongly implicated in the
process of WD (Court and Coleman, 2012), their importance in the
process of WD has also been questioned. Speciﬁcally, the protective
eﬀects of Wlds were still present in axon depleted of mitochondria
(Kitay et al., 2013) and while over expression of Nmnat2 was protective
to the axon, it does not appear to colocalise with the mitochondria
(Milde et al., 2013). Although changes in energy status and ATP pro-
duction have been implicated in WD, it has been suggested that this is
due to changes in glycolysis, rather than mitochondrial respiration
(Godzik and Coleman, 2015). Furthermore, although Sarm1 knockout
or an increase in Nmn levels can protect axons from degeneration, they
do no prevent changes in mitochondrial motility or depolarisation
(Loreto et al., 2015). The precise involvement of mitochondria in the
process of WD remains somewhat controversial, and further work is
required to deﬁne their involvement and importance in regulating axon
degeneration.
In this present study, we hypothesized that the observed accelera-
tion in the rate of synaptic and axonal WD is attributed to dynamic
changes in the postnatal nerve and muscle proteome. We utilized an ex-
vivo model of nerve injury to re-examine the age-dependent observa-
tions we reported previously (Murray et al., 2011). This conﬁrmed that
delayed NMJ degeneration was progressively lost between ages of P10
to P26. To address the mechanisms, we utilized tandem-mass tagging
quantitative mass spectrometry (TMT-QMS) to proﬁle the proteome of
both the nerve and muscle at 5 time points between P12 and P24. This
resulted in the identiﬁcation of 7440 and 6079 proteins in nerve and
muscle respectively. Following a bioinformatics-based reﬁnement of
the data, we employed pathway analysis of the most biologically re-
levant protein alterations to reveal an up-regulation in molecular net-
works implicated in oxidative phosphorylation (OXPHOS) and related
mitochondrial functions. Finally, we demonstrated that pharmacolo-
gical up-regulation of basal OXPHOS activity levels accelerated sy-
naptic degeneration, whilst exposure to the Complex I inhibitor rote-
none was strongly axoprotective. In summary, this study details post-
natal changes in the nerve muscle proteome, and identiﬁes protein
changes which can account for the delay in axon degeneration observed
in neonatal mice.
2. Materials and methods
2.1. Animal handling and husbandry
All procedures were performed in adherence with the guidelines set
out by the UK Home Oﬃce. MCos1 C56BL6/J mice were maintained
under Speciﬁc and Opportunistic Pathogen-Free conditions in breeding
facilities at the University of Edinburgh. All mice were sacriﬁced by an
overdose of anesthetic and cervical dislocation.
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2.2. Ex-vivo model of nerve injury
Mice ranging from P12 to P24 were sacriﬁced and immediately
dissected to minimize any post-mortem molecular changes. Hind legs
were removed and legs were microdissected in mammalian physiolo-
gical saline (MPS) of following ionic composition (mM): Na+ (158.4);
K+ (5); Ca2+ (2); Mg2+ (1); Cl− (145); HCO3– (24), H2PO4 − (0.4),
glucose (5); equilibrated by bubbling in 95%O2/5% CO2 to pH 7.2–7.4.
The deep lumbrical muscles with overlying FDB tendon and muscle
attached were dissected, along with the distal nerve stump of the sciatic
nerve, including all the nerve branches which innervate the lumbrical
muscles. This preparation therefore represented the muscles with at-
tached innervation, wherein the axons have been severed from the cell
body. This system therefore reﬂects an ex-vivo model of axon injury.
This preparation was pinned to dental wax and incubated for 24 h at
28 °C in oxygenated MPS bubbled continuously with 95/5% O2/CO2.
When speciﬁed, 2mM AICAR (Sigma) was added to oxygenated ringer
solution.
2.3. Immunocytochemical staining of nerve-muscle explants
Following 24 h incubation ex-vivo, nerve-muscle preparations were
incubated at room temperature with TRITC-conjugated α-bungarotoxin
at a concentration of 5 μg/ml in phosphate buﬀered saline to label
AChR at motor endplates. Preparations were ﬁxed at room temperature
for 15min in 4% paraformaldehyde in PBS, then incubated for 72 h at
4 °C with primary antibodies against synaptic vesicle protein (SV2), and
neuroﬁlament (2H3) at a concentration of 1:100 and 1:50 respectively
(Developmental Studies Hybridoma Bank, Iowa) then for 24 h at 4 °C in
FITC-conjugated IgG anti-mouse secondary antibody (Jackson).
2.4. Imaging and analysis
Endplate occupancy was quantiﬁed using a Leica DMi8 inverted
epiﬂuorescent microscope (10×, 20× and 40× objectives; 0.53, 0.55
and 0.9NA; Leica DMi9 microscope, Leica DFC7000-T camera).
Quantiﬁcation of endplate occupancy was performed blind, and in-
corporated a minimum of 50 NMJs from at least three distinct ﬁelds of
view per muscle per mouse (n= number of muscles, N=number of
mice), using the following criteria: fully occupied, i.e. complete cov-
erage of the post-synaptic endplate by the branches of the nerve
terminal; partially occupied, or vacant, ie. complete withdrawal of the
pre-synaptic terminal from the post-synaptic endplate.
Individual statistical tests and n numbers used are noted in ﬁgure
legends. Statistical signiﬁcance was considered to be p≤ 0.05.
Confocal microscopy was performed using a Nikon A1R+ Resonant
Scanning System (Nikon) (10× and 40× objectives; 0.3 and 1.3 oil NA;
Nikon A1R+ microscope; simultaneous image acquisition). 488 and
543 nm laser lines were used for excitation. The resultant confocal Z-
series produced in NIS Elements 2D Analysis software were exported
and merged using public domain Fiji ImageJ software downloadable
from https://ﬁji.sc/.
Figures were created using GNU Image Manipulation Program
(GIMP) for Windows.
2.5. Sample preparation for LC-MS/MS
Tandem mass tagging and fractionation of extracted samples was
performed by the FingerPrints Proteomics facilities at the University of
Dundee, to the following protocol:
Protein samples were thawed, trypsinised and desalted at room
temperature. 100 μg of desalted tryptic peptides per sample were dis-
solved in 100 μl of 100mM tetraethylammonium bromide (TEAB). The
10 diﬀerent tandem mass tag (TMT) labels comprising the TMT10plex™
kit (Thermo Fisher Scientiﬁc) were dissolved in 41 μl anhydrous acet-
onitrile. Each dissolved label was added to a diﬀerent sample; see Fig. 2
for the speciﬁcities of which label corresponded to which sample. The
sample-label mixture was incubated for 1 h at room temperature. La-
belling reaction was stopped by adding 8 μl of 5% hydroxylamine per
sample.
Following labelling with TMT, samples were mixed, desalted, and
dried in a speed-vac at 30 °C. Samples were re-dissolved in 200 μl am-
monium formate (NH₄HCO₂) (10mM, pH 10) and peptides were frac-
tionated using an Ultimate 3000 RP-High pH High Performance Liquid
Chromatography column (Thermo-Scientiﬁc) containing an XBridge
C18 column (XBridge peptide BEH, 130 Å, 3.5 μm, 2.1×150mm)
(Waters, Ireland) with an XBridge guard column (XBridge, C18, 3.5 μm,
2.1X10mm) (Waters, Ireland). Buﬀers A and B used for fractionation
consist, respectively, of (A) 10mM ammonium formate in milliQ water
and (B) 10mM ammonium formate with 90% acetonitrile. Before use,
both buﬀers were adjusted to pH 10 with ammonia. Fractions were
collected using a WPS-3000FC auto-sampler (Thermo-Scientiﬁc) at
1min intervals. Column and guard column were equilibrated with 2%
Buﬀer B for twenty minutes at a constant ﬂow rate of 0.2ml/min.
175 μl per sample was loaded onto the column at a rate of 0.2ml/min,
and the separation gradient was started 1min after sample was loaded
onto the column. Peptides were eluted from the column with a gradient
of 2% Buﬀer B to 5% Buﬀer B in 6min, and then from 5% Buﬀer B to
60% Buﬀer B in 50min. Column was washed for 16min in 100% Buﬀer
B and equilibrated at 2% Buﬀer B for 20min as mentioned previously.
The fraction collection started 1min after injection and stopped after
80min (total 80 fractions, 200 μl each). The total number of fractions
concatenated was set to 15 and the content of the fractions was dried
and suspended in 50 μl of 1% formic acid prior to analysis with LC-MS.
2.6. LC-MS/MS analysis
Liquid chromatography- tandem mass spectrometry was performed
by FingerPrints Proteomics Facilities at the University of Dundee, to the
following protocol: Analysis of peptide readout was performed on a Q
Exactive™ HF Hybrid Quadrupole-Orbitrap™ Mass Spectrometer
(Thermo Scientiﬁc) coupled with a Dionex Ultimate 3000 RS (Thermo
Scientiﬁc). LC buﬀers were made up to the following: Buﬀer A (2%
acetonitrile and 0.1% formic acid in Milli-Q water (v/v)) and Buﬀer B
(80% acetonitrile and 0.08% formic acid in Milli-Q water (v/v).
Aliquots of 15 μl per sample were loaded at a rate of 5 μl/min onto a
trap column (100 μm×2 cm, PepMap nanoViper C18 column, 5 μm,
100 Å, Thermo Scientiﬁc) which was equilibrated with 98% Buﬀer A.
The trap column was washed for 6min at the same ﬂow rate and then
the trap column was switched in-line with a resolving C18 column
(Thermo Scientiﬁc) (75 μm×50 cm, PepMap RSLC C18 column, 2 μm,
100 Å). Peptides were eluted from the column at a constant ﬂow rate of
300 nl/min with a linear gradient from 95% Buﬀer A to 40% Buﬀer B in
122min, and then to 98% Buﬀer B by 132min. The resolving column
was then washed with 95% Buﬀer B for 15min and re-equilibrated in
98% Buﬀer A for 32min. Q Exactive™ HF was used in data dependent
mode. A scan cycle was comprised of a MS1 scan (m/z range from 335
to 1800, with a maximum ion injection time of 50ms, a resolution of
120,000 and automatic gain control (AGC) value of 3×106) followed
by 15 sequential-dependent MS2 scans (with an isolation window set to
0.4 Da, resolution at 60000, maximum ion injection time at 200ms and
AGC 1×105. To ensure mass accuracy, the mass spectrometer was
calibrated on the ﬁrst day that the runs were performed.
2.7. Database search and protein identiﬁcations
Raw MS data from the 15 fractions were searched against mouse
(Mus musculus) protein sequences from UniProtKB/Swiss-Prot using the
MASCOT search engine (Matrix Science, Version 2.2) through Proteome
Discoverer™ software (Version 1.4, Thermo Fisher). Parameters for
database search were as follows: MS1 Tolerance: 10 ppm; MS2
Tolerance: 0.06da; ﬁxed modiﬁcation: Carbamidomethyl (C) Variable
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Modiﬁcation: Oxidation (M), Dioxidation (M), Acetyl (N-term), Gln-
> pyro-Glu (N-term Q), TMT 10(N-term and K); maximum missed
cleavage: 2; and target FDR 0.01.
All identiﬁcations were quantiﬁed as relative ratios of expression
compared to the ﬁrst time point (P12) through Proteome Discoverer™
software (Thermo Fisher, Version 1.4). Relative ratios along with
UnitProtKB/Swiss-Prot identiﬁcations were exported into Microsoft
Excel as a raw data ﬁle containing ID, ratio of change in expression at
each time point (P15, P18, P21, P24) compared to P12=1.
2.8. Selection of relevant expression clusters from ﬁltered data in BioLayout
Express3D
Filtering raw proteomic data by an expression change of> 20% at
P24 than at P12 in produced a separate ﬁltered list of proteins in nerve
and muscle. These lists were imported separately into BioLayout
Fig. 1. An ex-vivo system conﬁrms decreased rate of axon degeneration in Wlds and neonatal mice. (A) Representative confocal micrographs of NMJs from age-
matched adult C57BL/6 J wildtype andWldS mouse lumbrical muscles after 24 h incubation ex-vivo at 28 °C in oxygenated ringer solution. Note the retention of NMJ
integrity in theWldS model compared to the marked loss of pre-synaptic inputs in the wildtype muscle. Scale bar= 25 μm (B) Bar chart (Mean ± SEM) showing the
percentage of fully occupied endplates 24 h post-axotomy reveals an increased in the percentage of fully occupied endplates in WldS mice compared to wildtype
C57BL/6 J mice. (*p < 0.05 by Mann-Whitney U test; n=3 preparations per group, data are Mean ± SEM). (C) Representative confocal micrographs of NMJs from
the deep lumbrical muscles from P10, P15, P21 and P26 mice after 24 h incubation ex-vivo at 28 °C in oxygenated mammalian physiological saline. Note the increase
in vacant endplates (denoted by arrowhead) at P21 and P26 compared to P12 and P15. Scale bar= 25 μm (D) Bar chart (Mean ± SEM) of the percentage of fully
occupied endplates in the deep lumbrical muscles from P12, P15, P21 and P26 mice conﬁrms an age-associated decrease in the percentage of fully occupied
endplates. (***p < 0.001, by Kruskall-Wallis test; n=3 preparations per group.
R.A. Kline, et al. Neurobiology of Disease 130 (2019) 104496
4
Express3D (Theocharidis et al., 2009) and clustered based on relative
expression proﬁle from P12 to P24. Algorithms in BioLayout Express3D
generate a visual network to represent each data set, utilizing special
proximity to represent the similarity in expression proﬁle of individual
proteins over time. The resultant visual networks were utilized to dis-
tinguish expression clusters that followed either a general upward or
downward trend in expression from P12 to P24. These “upregulated”
and “downregulated” clusters in nerve and muscle respectively were
analyzed on an individual basis to exclude clusters that did not follow
an experimentally relevant expression proﬁle from P12 to P24. For
example, clusters containing proteins that exhibited a consistent in-
crease or decrease in expression were selected, while clusters consisting
of proteins that exhibited an overall upregulation or downregulation
but oscillated in expression during middle time points were excluded.
2.9. DAVID analysis
Proteins exhibiting a consistent up-regulation or down-regulation in
nerve or muscle from P12 through all four subsequent time points to
P24, regardless of magnitude of change, were submitted as a gene list
and converted into DAVID IDs against the DAVID 6.7 Mus musculus
database(Huang et al., 2009). Four separate analyses were performed
from the following lists of proteins, grouped as: (1) Consistent upre-
gulated expression in nerve, (2) Consistent downregulated expression in
nerve, (3) Consistent upregulated expression in muscle, and (4) Con-
sistent downregulated expression in muscle. These lists were analyzed
using the Functional Annotation Clustering tool in DAVID Bioinfor-
matics Resources (Version 6.7) to produce a list of functional annota-
tions. Functional annotations are ranked by a DAVID enrichment score.
Fig. 2. Schematic of sample preparation, TMT 10plex™ Tandem Mass Tag labelling, and quantitative LC-MS/MS workﬂow. (A, B) Images showing region of sciatic
nerve (A) or lumbrical muscles (B) which were isolated for proteomics (C) Schematic of sample preparation workﬂow for TMT 10plex™ labelling and subsequent LC-
MS/MS. Sciatic nerves (n=5 mice, 10 nerves) and lumbrical muscles (5 mice, 20 muscles per timepoint) were pooled for a single extraction in label-free buﬀer per
timepoint. Pooled samples were labelled using all 10 isobaric mass tags from a TMT 10plex™ kit (Thermo Fisher). Labelled samples were prepared for LC-MS/MS and
run in technical triplicate. Scale bars= 2mm.
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An enrichment score> 1.3 in DAVID is equivalent to p < 0.05, and
considered to be statistically signiﬁcant.
2.10. In silico protein pathway analysis
The Ingenuity Pathway Analysis (IPA) application (Ingenuity
Systems, Silicon Valley, CA) was used to visualize and explore the
cellular and molecular pathways that may have been altered as a result
of expression changes over time. IPA generates networks of gene and
protein interactions and disease associations, amongst other results,
based on in silico predicted or experimentally reported interactions
stored within the “hand-curated” Ingenuity Knowledge database
(Wishart et al., 2012; Savli et al., 2008). The majority (90%) of data
comprising the Ingenuity Knowledge database are derived from peer-
reviewed publications; the remaining 10% of stored interactions have
been identiﬁed by other in silico techniques. Networks generated using
IPA were set to a maximum of 35 member molecules, and were ranked
according to a score calculated by a right-tailed Fisher's exact test,
which considers total protein input and size of the produced network.
Network scores represent the relevance of the particular network to the
overall analysis (i.e. proteomic alterations in nerve or muscle between
P12 and P24). In this study, networks generated using IPA were limited
to those producing the top 25 scores. For more information on the
computational methodology underpinning IPA, please refer to http://
www.ingenuity.com/.
Separate pathway analyses were performed on the ﬁltered nerve
and muscle data sets, which produced 25 predictive molecular net-
works each. A third, combined analysis, which consolidated nerve and
muscle results, enabled the identiﬁcation of molecular overlap within
networks generated from nerve and muscle data. Extrapolation of this
overlap through the Pathway Designer function generated a combined
network in which molecular interactions conserved between both nerve
and muscle data sets were explored.
2.11. Complex I activity assay
Mitochondrial OXPHOS Complex I activity was determined by im-
munocapture ELISA kit following the manufacturer's instructions
(ab109721). Nerve (sciatic, brachial plexus, intercostal nerves) and
muscle (deep lumbrical muscle) were isolated from recently sacriﬁced
mice and snap-frozen on dry ice prior to assay. Thawed tissue was
homogenized in ice-cold PBS with Dounce homogenizer and protein
extracted with detergent solution at a concentration of 1:10. 250 μg of
protein was incubated to the wells of microplate pre-coated with
Complex I capture antibody for 3 h at room temperature. Activity of
immunocaptured Complex I enzyme (NADH dehydrogenase) was de-
termined by measuring the oxidation of NADH to NAD+ and si-
multaneous reduction of a dye which leads to increased absorbance at
450 nm. Each reaction was performed in duplicate. Activity was ex-
pressed as a change in absorbance per minute per quantity of protein
per reaction, and values are expressed normalized to P12.
2.12. Quantitative ﬂuorescent western blotting
Levels of Complex I protein were determined by quantitative
ﬂuorescent western blot (QFWB). Gastrocnemius muscles were isolated
from recently sacriﬁced mice and snap-frozen on dry ice prior to im-
munoblotting. Thawed tissue was homogenized in ice-cold PBS with
Dounce homogenizer and extracted in RIPA buﬀer (Fisher Scientiﬁc)
with 1% Halt protease inhibitor cocktail (Sigma Aldrich).
Concentration of protein was determined by micro-BCA assay (Pierce
Biosystems). Samples were prepared to load 25 μg of protein in 10 μl
deionised water and 5 μl of NuPage® LDS Sample buﬀer 4×
(Invitrogen, UK) and run on a NuPAGE™ Novex™ 4–12%Bis-Tris protein
gel (Invitrogen, UK) before transfer to a PVDF membrane using the i-
Blot2® transfer system (Invitrogen, UK).
To determine total protein concentration for a loading control,
membranes were incubated in 5ml of Ponceau S solution; 0.1%
Ponceau S (Sigma-Aldrich), 0.5% acetic acid (Sigma-Aldrich) in ddH2O
at room temperature for 30min before washing in ddH2O until bands
were visible. Total protein image was scanned in greyscale using a
CanoScan LiDE220 digital scanner (Canon) and saved as a TIFF image
for total protein analysis.
For QFWB, membranes were blocked in 5ml Odyssey® Blocking
Buﬀer (Li-COR Biosciences) at room temperature for 30min and in-
cubated in primary antibody solution containing primary antibodies at
the following concentration (SIRT2 1:500, Abcam; Igf2 1:1000, Abcam;
Total OXPHOS 1:1000, Abcam) with 1% tween-20 (Sigma) in 5ml
Odyssey® Blocking Buﬀer (Li-COR Biosystems) at 4 °C overnight.
Antibody to SIRT2 was generously provided by members of the
Gillingwater laboratory. Membranes were incubated in secondary an-
tibody solution containing either IRDye® 680RD donkey anti-mouse IgG
(H+ L) or IRDye® 680RD donkey antirabbit IgG (H+L) antibodies (Li-
COR Biosciences) at a concentration of 1:5000 (0.02%) in a solution of
1% tween-20 (Sigma) in 5ml Odyssey® Blocking Buﬀer (Li-.
COR Biosciences for 90min at room temperature before drying and
storage at 4 °C prior to imaging and analysis. For measurement and
analysis, TIFF images of Ponceau-stained blots were imported into
Odyssey® ImageStudio Lite software (Version 5.2). ImageStudio Lite
(Version 5.2) was used to analyze the intensity of identical sections of
total protein banding against background. Readouts of the intensity of
total protein banding relative to background were imported into
Microsoft Excel (Windows 2013) to calculate loading consistency and
normalization factors. Western blots were imaged on the 700 nm
channel using the Odyssey® Infrared Imaging System at a resolution of
169 μm. All quantiﬁcation was performed on the 700 nm channel, with
the intensity of bands normalized using the factors generated from total
protein analysis. All statistical analysis and generation of graphs was
performed in GraphPad Prism7 (Windows). Individual statistical tests
used are noted in ﬁgure legends. Statistical signiﬁcance was considered
to be p≤ 0.05.
2.13. Dorsal root ganglion cultures
Brieﬂy, E16 rat embryos were decapitated, and the limbs and organs
were removed. The spinal cord with dorsal root ganglia (DRGs) was
dissected and placed in a Petri dish containing cold L-15 medium
(Gibco, 11,415–064). For DRG explants, complete DRGs were cultured
in 24-well dishes containing 400 μl of Neurobasal medium, 2% B27,
0.3% L-glutamine, 1% streptomycin/penicillin, 4 μM aphidicolin
(Sigma, A0781), 7.5 μg/ml 5-ﬂuoro-2- deoxyuridine (Sigma, F0503),
and 50 ng/ml nerve growth factor (NGF) (Invitrogen, 13,257–019). The
mixture of aphidicolin and ﬂuoro-2-deoxyuridine inhibits proliferation
of Schwann cells by inhibition of DNA polymerase (Spadari et al., 1985;
Wallace and Johnson Jr., 1989), thus constituting a highly pure sensory
neuron culture (Heermann et al., 2012). DRGs were cultured for
7–11 days at 37 °C and 5% CO2. Axotomy of DRG explants was made
using a micropipette tip to separate all the axons from their somas.
2.14. Axonal degeneration index
Number of axons per area of nerve tissue was assessed in confocal
images of neuroﬁlament-immunostained explant sections (matched for
laser power, photomultiplier tube gain/oﬀset, and post processing)
using the particle analysis macro of ImageJ. Relative neurite integrity
was based on the ratio of the areas of fragmented axons versus total
axonal area (Villegas et al., 2014). Degenerated axon fragments were
detected using the particle analyzer algorithm of ImageJ (NIH, USA)
and the total fragmented axon area versus total axonal area was used to
estimate a degeneration index.
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2.15. DHE assay
Superoxide levels were measured using dihydroethidium (DHE)
ﬂuorescence 6 h after DRG axotomy in an epiﬂuorescence microscope.
After axotomy, neurites were incubated in the last 30min with 5M DHE
under culture conditions. DHE ﬂuorescence was obtained under a Cy5
emission ﬁlter. Superoxide levels on neurites were determined using
NIH ImageJ colocalization highlighter plugin. Oxidative stress levels
were calculated as the ratio of DHE ﬂuorescent signal area in neurites.
Brieﬂy, DHE signal and phase-contrast colocalization were used to
obtain DHE area and neurite length. Photoshop (Adobe Systems) and
NIH ImageJ were used to perform this analysis.
3. Results
Previous work has demonstrated that axotomised NMJs from neo-
natal mice showed a reduced rate of WD compared to NMJs from adult
mice under otherwise identical experimental conditions (Murray et al.,
2011). Between postnatal day 12 (P12) and P24 the rate of axotomy
induced degeneration accelerates until the adult response of rapid sy-
naptic degeneration is established. We ﬁrst sought to determine whe-
ther age-dependent regulation of synaptic degeneration could be re-
plicated using an “ex-vivo” assay of synaptic degeneration (Brown et al.,
2015). Nerve-muscle preparations, comprising the tibial nerve and all
branches innervating the attached deep lumbrical muscles were swiftly
isolated from euthanized mice, and maintained in oxygenated physio-
logical solution, then assayed for innervation 24 h later. This protocol
mimics axotomy in vivo (Brown et al., 2015). Comparison of endplate
occupancy at immunostained NMJs from the deep lumbrical muscles
from adultWldS mice revealed that, as expected, the percentage of fully
occupied NMJs was signiﬁcantly greater than that of NMJs from age-
matched wild-type C57BL/6 adults (Fig. 1A, B). Thus, this assay is
suﬃciently sensitive to reveal factors that inﬂuence the rate of WD.
Equivalent preparations were isolated from mice aged P10 to P26.
Analysis of NMJs from the lumbrical muscles revealed a signiﬁcant
decrease in the percentage of fully occupied endplates between P10 and
P26 (Fig. 1C,D). Together, the data suggest that an ex-vivo model of
traumatic injury can be used to detect diﬀerences in the rate of axon
degeneration and conﬁrms the age-associated decrease in the rate of
axon degeneration in mice aged between P10 and P26.
3.1. Tandem mass tagging (TMT) quantitative proteomics produces a robust
and comprehensive coverage of the nerve and muscle proteome
The combination of published work and the data presented above
clearly demonstrate a marked increase in the rate of WD during the
neonatal time period. We therefore reasoned that whatever regulates
this progressive increase in the rate of WD, may also be changing
progressively over the time period between P12 and P24. Given that the
process of WD occurs after the axonal and synaptic compartments of the
cell are severed from the cell body, and the overall speed of WD, we
reasoned that the molecular regulators of this process would be most
likely evidenced at the protein level, as opposed to at the level of
transcription. We therefore performed a comprehensive proteomic
analysis of muscle and nerve between P12 and P24, with the goal of
identifying proteins and cellular processes which demonstrated a steady
alteration correlating with the change in the rate of axon degeneration.
For this analysis, we employed tandem mass tagging (TMT) based
proteomics using a 10plex (TM) labelling kit to allow comparative
protein proﬁling across ten diﬀerent sample groups. For this analysis we
collected deep lumbrical muscle and sciatic nerve samples from mice
aged P12, P15, P18, P21 and P24 and performed TMT proteomic ana-
lysis (Fig. 2). Consolidation of raw peptide outputs across all ﬁve time
points within sciatic nerve and muscle samples respectively were
translated into protein identiﬁcations by searching against murine
protein sequences using the MASCOT protein database (Matrix Science,
Version 2.2) and quantiﬁed expression as relative ratios compared to
the ﬁrst time point (P12) in each tissue type. This produced a list of
protein identiﬁcations and ratios of expression/detection throughout
the time course for muscle and nerve (see Methods for more informa-
tion). Both nerve and muscle analyses are traditionally faced with the
problem of detection saturation due to particularly abundant protein
groups i.e. myelin related proteins in nerve or myosin groups in muscle
(Comley et al., 2011; Mutsaers et al., 2013, 2011). The application of
TMT combined with developments in sample handling workﬂows
(smaller sample requirements, reduced processing losses, greater frac-
tionation control) and recent technological advances in mass spectro-
metry sensitivity, has resulted in an unexpectedly high number of re-
liable protein identiﬁcations in all sample groups.
Within the sciatic nerve, 7440 total proteins were identiﬁed, of
which 5625 were identiﬁed by 2 or more unique peptides
(Supplementary Table 1). Within the lumbrical muscles, 6079 total
proteins were identiﬁed, of which 4414 were identiﬁable by>2 unique
peptides (Supplementary Table 2).
Having identiﬁed so many proteins in both nerve and muscle, we
applied a ﬁltering protocol in order to identify protein alterations which
are likely to be biologically relevant to the phenomenon of early age
dependent neuronal stability. Thus, we began by further ﬁltering the
proteomic output to exclude any proteins with altered expression<
20% in either direction at P24 compared to P12. Previous studies in
neural tissue and skeletal muscle have demonstrated that the 20% cut-
oﬀ threshold produces a reliable list of candidate molecules (Comley
et al., 2011; Mutsaers et al., 2013, 2011; Aghamaleky Sarvestany et al.,
2014; Fuller et al., 2014).
In order to identify proteins whose expression are likely to correlate
with the diﬀerential vulnerability described above, we used the net-
work-based software BioLayout Express3D. This software uses complex
pattern recognition algorithms to cluster data by user-deﬁned dimen-
sions, while generating visual networks that utilize spatial proximity to
represent relatedness. By clustering our reﬁned protein list based on
protein expression proﬁle over the 5 time points, it was possible to
visualize and isolate clusters of proteins exhibiting similar expression
proﬁles over the time-course. We were therefore able to further ﬁlter
the nerve and muscle data sets to include only those candidates which
exhibited a desirable expression proﬁle over the experimental P12-P24
period (Fig. 3). Speciﬁcally, clusters which exhibited a relatively con-
sistent up-regulation or down-regulation in expression from P12 to P24
were selected for further analysis. Conversely, clusters containing pro-
teins which showed a discontinuous expression proﬁle, for example,
those oscillating between an increase and decrease over the experi-
mental period, were excluded. Through this ﬁltering process, we pro-
duced a consolidated data set containing only proteins exhibiting a
relative change in expression> 20% at P24 relative to P12 and an
experimentally relevant expression proﬁle (Supplementary Tables 3
and 4).
To validate the proteomic data, we performed quantitative ﬂuor-
escent western blotting on protein candidates selected from the raw LC-
MS/MS output. Candidates were selected on the basis of their magni-
tude of change over the experimental period, implication in injury-in-
duced or disease-related neuronal degeneration, and availability of
quality antibodies suitable for ﬂuorescent-based western blotting. For
example, the NAD-dependent deacetylase sirtuin-2 (SIRT2) exhibited
an increase in the proteomic data (1.330 P24/P12 ratio in nerve) and
has been demonstrated to be up-regulated across a number of neuro-
degenerative disease and injury models (Allodi et al., 2016; Amorim
et al., 2015; Graham et al., 2017; Hedlund et al., 2010; Murray et al.,
2015; Zhang et al., 2013). Quantitative ﬂorescent western blot analysis
conﬁrmed a consistent increase in protein levels observed between P12
and P24 (1.44 ± 0.06, P24/P12 ratio of Mean ± SEM; Fig. 4A,B).
Additionally, the neurotrophic factor insulin-like growth factor 2 (IGF2)
exhibited a decrease in the proteomic data (0.410 P24/P12 ratio in
muscle) and has been implicated in in a mouse models of motor neuron
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disease (Allodi et al., 2016; Hedlund et al., 2010; Murray et al., 2015;
Zhang et al., 2013). Quantitative ﬂuorescent western blot analysis on
protein extracted from lumbrical muscle (IGF2) conﬁrmed a consistent
decrease in protein levels observed between P12 and P24
(0.402 ± 0.044, P24/P12 ratio of Mean ± SEM; Fig. 4A,C). Thus,
these results conﬁrm the direction and magnitude of expression change
reported in our proteomic proﬁling.
3.2. Functional annotation analysis of ﬁltered nerve and muscle data
reveals a conserved enrichment for proteins related to oxidative
phosphorylation and mitochondrial bioenergetics
The reﬁned nerve and muscle data sets were sorted into four lists:
(1) consistent up-regulated expression in nerve, (2) consistent down-
regulated expression in nerve, (3) consistent up-regulated expression in
muscle and (4) consistent down-regulated expression in muscle. These
lists were analyzed using the Functional Annotation Clustering tool in
DAVID Bioinformatics Resources (Version 6.7) to determine if the
proteins whose expressions trend together share functional annotations.
Interestingly, consistently up-regulated protein groups within the
sciatic nerve revealed a marked enrichment for processes implicated in
oxidative phosphorylation and mitochondrial respiration (Table 1). The
most signiﬁcantly enriched group was comprised of proteins involved
in NAD-dependent “redox” processes. Analysis of proteins consistently
down-regulated within the sciatic nerve was dominated by the presence
of biological groups involved in mRNA processing and binding, as well
as RNA-editing machinery such as the RNP complex and spliceosome
(Table 1). Other top groups contained proteins pertaining to en-
doplasmic reticulum activity.
In the muscle, analysis of proteins consistently up-regulated also
revealed an enrichment of processes relating to mitochondria, speciﬁ-
cally (as with nerve) oxidative phosphorylation (Table 2). Indeed, all
“top-5” biological groups produced by this analysis were clusters in-
volved in electron transport chain activity or broader mitochondrial
functions. Analysis of proteins consistently down-regulated within the
lumbrical muscles identiﬁed endoplasmic reticulum (similar to nerve),
protein transport, membrane-bound vesicles, and actin-binding
(Table 2). Thus, the functional clustering analysis suggest a general
shared consistent increase in proteins pertaining to mitochondria, oxi-
dation reduction and the electron transport chain in muscle and nerve.
3.3. In silico pathway analysis reveals conserved direct interactions between
components of the oxidative phosphorylation pathway in both muscle and
nerve
Given the enrichment for proteins associated with mitochondrial
functions within our reﬁned candidate lists, we next employed IPA
software to our cluster-derived lists in order to contextualize these
protein changes into speciﬁc cellular cascades with the aim of identi-
fying potential intervention points, as performed previously
(Catenaccio et al., 2017; Graham et al., 2017; Llavero Hurtado et al.,
2017). Unlike other network-based approaches, IPA generates mole-
cular networks based on interactions reported in its “hand-curated”
database, with the option for restricting analyses to only experimentally
Fig. 3. Filtering of raw proteomic data produces an analysis-ready dataset of experimentally relevant proteins. (A,B) Scatter plot depicting the ﬁltering process
undertaken on raw proteomics nerve data (LC-MS/MS output identiﬁed by 2 more unique peptides) through manual selection of relevant expression clusters to
generate a ﬁnal list of 1734 proteins exhibiting consistent increases or decreases in expression in the murine sciatic nerve (A) or lumbrical muscle(B). Data are
presented as expression ratios (P12/P24) and each data points represents an individual protein. (C-F) Graphs displays the relative change in protein levels relative to
P12 of protein clusters, clustered on the basis of a similar trend, which display a desirable proﬁle of continuous increase (C,E) or continuous decrease (D,F) in levels in
either sciatic nerve (C,D) or lumbrical muscle (E,F). Cluster generated in BioLayout Express3D from the ﬁltered nerve dataset (exhibiting a > 20% change in relative
expression at P24 from P12). Proteins within these clusters feature a steady relative increase or decrease in levels over the P12-P24 time period, and were therefore
selected for future analysis.
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reported interactions. Initially, this analysis was performed on nerve
and muscle data sets independently. This analysis of nerve and muscle
included all mappable proteins from both nerve and muscle data sets
(1713 and 1862 respectively) and were analyzed in parallel, with in-
teractions restricted to only those reported experimentally (as opposed
to in silico predictions). The ﬁltered list of proteins from nerve and
muscle were imported into IPA and of these,> 98% were mappable by
the software and therefore suitable for data mining of the published
literature to generate interaction networks. As expected, this revealed
molecular networks dominated by proteins pertaining to mitochondrial
respiratory components, speciﬁcally, components of the electron
transport chain—and redox sensitivity in both muscle and nerve
(Supplementary Figs. 1 and 2).
We next utilized the Path Designer function in IPA to identify a
molecular overlap between the predicted networks generated from the
previous independent nerve and muscle analyses. Extrapolation of this
convergence into a visual network, organized by cellular location, re-
vealed the conservation of multiple direct interactions between com-
ponents of the electron transport chain in both nerve and muscle data
sets, with a speciﬁc enrichment for factors involved with Complex I and
IV (Fig. 5). In accordance with the previous functional annotation
analyses of nerve and muscle data sets, these results demonstrated an
Fig. 4. Candidate validation of proteomic data by quantitative ﬂuorescent Western blotting. (A) Representative western blots for NAD-dependent deacetylase sirtuin-
2 (Sirt2) in nerve and insulin-like growth factor 2 (Igf2) in muscle. All candidate blots were normalized to total protein load (Ponceau S stain) (B,C) Scatter plots
(individual data points; Mean ± SEM) of relative expression of Sirt2 (B) and Igf2 (C) relative to P12. Note direction and magnitude of change is consistent with TMT
data. (n= 3 pairs of nerves (SIRT2) or 8 lumbrical muscles (IGF2) per time point; **p < 0.01, ***P < 0.001 by Kruskall-Wallis test).
Table 1
Top 5 most signiﬁcantly enriched functional clusters in sciatic nerve.
Up from P12-P24 Down from P12-P24
Cluster name Enrichment score Cluster name Enrichment score
Mitochondrial oxidation reduction; NAD-dependent 8.44 mRNA processing/Spliceosome 25.24
Cell fraction 4.61 RNP complex/ribosome 23.19
Cytoskeletal actin binding 4.53 RNA binding 16.1
Membrane lipoproteins 4.26 Intracellular organelle lumen 12.54
Magnesium binding 4.06 Endoplasmic reticulum 11.87
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Table 2
Top 5 most signiﬁcantly enriched functional clusters between P12 and P24 in the lumbrical muscles.
Up from P12-P24 Down from P12-P24
Cluster name Enrichment score Cluster name Enrichment score
Mitochondria 134.15 Endoplasmic reticulum 12.26
Mitochondrial membrane 82.63 Protein transport 10.38
Oxidation reduction/electron transport chain (ETC) 43.65 Membrane-bound vesicle 9.81
Electron transport/oxidoreductase/NADH dehydrogenase activity 25.4 Actin binding/actin cytoskeleton 8.89
Cellular respiration/electron transport chain 22.5 Actin cytoskeleton organization 8.52
Fig. 5. Combined analysis in nerve and muscle reveals conserved escalation in mitochondrial oxidative phosphorylation related proteins. Use of the Path Designer
function in IPA software, to reveal combined interaction network, reveals an overlap in molecular interactions pertaining to the mitochondrial oxidative phos-
phorylation process. Speciﬁcally, candidates identiﬁed as components of mitochondrial Complex I (NADH dehydrogenase) and Complex IV (cytochrome c oxidase)
exhibit conserved expression changes in both nerve and muscle data sets. Proteins within this network reﬂect those which up-regulated (red) and down-regulated
(green) during the P12-P24 time-course in either nerve or muscle; intensity of colour corresponds with magnitude of expression change. White represents a molecule
that is absent from both datasets but an important component of the network. Grey represents a molecule that is present in the datasets but the change in levels is
below the 20% cut-oﬀ. Solid connecting lines represent a direct interaction, while dashed connecting lines indicate an indirect interaction. Interactions conserved
between nerve and muscle data sets are highlighted as purple connecting lines. Blue connecting lines represent the highlighted interactions of NADH dehydrogenase.
All suggested indirect interactions were conﬁrmed manually using the IPA software to identify publications indicating an experimentally reported interaction
between the two components. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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increased expression in proteins involved in the mitochondrial electron
transport chain over the P12-P24 period. This suggests that diﬀerences
in mitochondrial electron transport chain component expression and/or
activity may serve as a key hub for the regulation of the molecular
processes being mapped out through this temporal proﬁling of pro-
gressive vulnerability.
We next performed enzyme-linked immunosorbance assays (ELISA)
of Complex I NADH dehydrogenase activity in order to determine
whether our in silico-derived suggestion of an increase in Complex I
expression was accompanied by a functional increase of Complex I
activity. Analysis of these results suggested a consistent increase of
Complex I activity in both the nerve and skeletal muscle of P24 com-
pared to P12 mice, which reached statistical signiﬁcance in muscle
(Fig. 6A,B). We also aimed to assess the expression of Complex I by
quantitative ﬂuorescent western blotting, and conﬁrmed an increase in
Complex I expression levels in the skeletal muscle of P24 mice com-
pared to P12 mice as predicted (Fig. 6C,D). This therefore conﬁrms the
validity of the data ﬁltering strategy employed and the identiﬁed mo-
lecular cascades being represented in the subsequent in silico analysis.
3.4. Inhibition of Complex I prevents the rise in reactive oxygen species and
protects axons following injury
The above data indicate that an increase in Complex I of the mi-
tochondrial respiratory chain correlates with the acceleration in the
rate of axon degeneration in response to injury. We therefore aimed to
determine whether inhibition of Complex I could delay axon degen-
eration. For these experiments, we employed the Complex I inhibitor,
rotenone and used an established murine dorsal root ganglion primary
culture model (Lopez-Leal et al., 2018). This model has the beneﬁt of
allowing us to assess axon intrinsic factors regulating axon degenera-
tion. 12 h after axotomy (induced by severing cell bodies from their
axons), robust degeneration was observed in control cultures, as evi-
dence by widespread fragmentation of neuroﬁlament labelled axons
(Fig. 7A). However, in cultures exposed to 10 μM rotenone, axonal
fragmentation was visibly reduced. Quantitation of the degree of axon
degeneration revealed a signiﬁcant decrease in cultures treated with
rotenone, to levels similar to those of non-injured controls (Fig. 7B),
demonstrating that inhibition of Complex I can indeed be protective to
the axonal compartment of neurons.
Reactive oxygen species (ROS) have previously been implicated in
axon degeneration (Barrientos et al., 2011; Villegas et al., 2014;
O'Donnell et al., 2013; Park et al., 2013; Calixto et al., 2012). As
Fig. 6. Complex I activity and levels are up-regulated between P12 and P24 in muscle and nerve. (A, B) Bar chart (Mean ± SEM) showing Complex I (NADH
dehydrogenase) activity in P12 and P24 sciatic nerve (A) and lumbrical muscle (B). NADH dehydrogenase activity was measured kinetically over 60min and the rate
was determined as change in optical density over time, and expressed normalized to P12 (n= 3 biological replicates, 5 mice per group; ** P < 0.05 by Mann
Whitney U test). (C) Image showing example western blot using antibodies against Complex I subunit on muscle from P12 and P24 mice, with Ponceau S staining
showing total protein as a loading control. (D) Bar chart (Mean ± SEM) showing quantiﬁcation of western blot against Complex I. Data expressed normalized to
loading control and relative to levels at P12. (N=3 biological replicates, 5 mice per time point, * P < 0.05 by Mann Whitney U test).
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Complex I is a major source of reactive ROS, we hypothesized that the
protection following Complex I inhibition may be linked to a decrease
in ROS. Dihydroethidium (DHE; a Redox sensitive ﬂuorescent probe)
was applied to DRG cultures. 6 h following axon injury, a signiﬁcant
increase in DHE ﬂuorescence was observed compared to non-injured
controls (Fig. 7C,D). However, in cultures treated with rotenone, DHE
ﬂuorescence remained similar to non-injured controls, and was sig-
niﬁcantly reduced compared to untreated cultures. Together, these data
suggest that inhibition of Complex I via rotenone can inhibit the ax-
otomy related rise in ROS and prevent axon degeneration.
3.5. Up-regulating basal OXPHOS at P15 accelerates degeneration of NMJs
The data thus far reveal an up-regulation in oxidative phosphor-
ylation between P12 and P24, which coincides with the acceleration of
WD with postnatal age. This data support the hypothesis that a decrease
in Complex I activity results in the neuroprotective phenotype observed
in neonatal mice. We therefore asked whether experimentally upregu-
lating basal OXPHOS levels would abolish the delayed WD phenotype
in neonatal mice. Adenosine monophosphate kinase (AMPK) is capable
of sensing AMP levels and impacts upon downstream pathways, most
markedly those acting upon the energy status of the cell. Activation of
AMPK via the AMPK agonist AICAR results in up-regulation of oxidative
metabolism (Golubitzky et al., 2011; Jager et al., 2007; Pacelli et al.,
2015). In order to determine whether stimulation of mitochondrial
activity could accelerate axon degeneration, we used an ex-vivo assay of
nerve-muscle preparations from P15 mice in either the presence of
absence of AICAR. Addition of 2mM AICAR signiﬁcantly enhanced the
rate of NMJ degeneration after 24 h ex-vivo (Fig. 8). This suggest that
increasing the amount of proteins related to (and thus overall activity
of) oxidative phosphorylation between P12 and P24, could account for
the acceleration of WD in vivo. Together with the ﬁndings above, these
data support the notion that the changes in mitochondrial proteins
observed between P12 and P24 could account for the acceleration in
the rate of WD in this same time window.
4. Discussion
In this study we applied a tandem mass tagging method to quanti-
tatively proﬁle the proteome of the nerve and muscle over a critical
period of postnatal development when the rate of WD following axonal
injury is increasing. The data suggest that elevation in proteins asso-
ciated with mitochondria and oxidative phosphorylation closely ac-
companies the acceleration in WD of the distal compartments of the
motor neuron following axotomy. Speciﬁcally, there was a shared in-
crease in protein expression associated with Complex I and IV of the
OXPHOS pathways in both muscle and nerve. An increase in both the
activity and levels of Complex I was conﬁrmed in muscle. We also de-
monstrate that inhibition of Complex I prevents the axotomy related
rise in ROS and protects the axon from degeneration. Finally, using the
ex-vivo model of neuronal injury, we demonstrate that up-regulating
basal OXPHOS levels ablates the delay in WD observed in neonatal
mice. These ﬁndings imply a regulatory role for mitochondria in sy-
naptic maintenance and degeneration. The data also provide evidence
for a dynamically evolving postnatal proteome, including altered levels
of mitochondrial proteins that can inﬂuence sensitivity to triggers of
synaptic and axonal degeneration.
Fig. 7. Rotenone protects axons and ameliorates rise
in ROS in a DRG model of axon injury. A)
Fluorescent images show axons from dorsal root
ganglion primary cultures labelled with antibodies
against neuroﬁlament heavy chain (NF-H) which are
either non-injured or 12 h post axotomy. Note
widespread axon fragmentation following axotomy
which is prevented by treatment with 10 μM rote-
none. Scale bar= 20 μM B) Bar chart
(Mean ± SEM) shown axon degeneration index in
non-injured (Control/Rot) on injured (Axot/Axot +
Rot) cultures which were either untreated (Control/
Axot) or exposed to 10 μM Rotenone (Rot/Axot
+Rot). **** P < 0.0001 Axot compared to all other
groups, ANOVA with Tukeys multiple comparison
test. C) Fluorescent images show axons from dorsal
root ganglion primary cultures labelled with DHE
which are either non-injured or 6 h post axotomy.
Note increase in ﬂuorescence following axotomy
which is not observed following treatment with
10 μM rotenone. Scale bar= 20 μM D Bar chart
(Mean ± SEM) shown DHE ﬂuorescence in non-in-
jured (Control/Rot) on injured (Axot/Axot + Rot)
cultures which were either untreated (Control/Axot)
or exposed to 10 μM Rotenone (Rot/Axot + Rot).
**P < 0.01; *P < 0.05; ANOVA with Tukeys mul-
tiple comparison test.
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4.1. Implications of the evolving postnatal proteome for neuromuscular
disease
The ﬁndings we present in this study demonstrate that a broad
range of molecular pathways evolve steadily and dynamically over
postnatal development. It is therefore likely that a broad array of mo-
lecular pathways, including those potentially impacting upon patho-
genic cascades, could be markedly inﬂuenced by the age of the in-
dividual. This immediately invites consideration into the family of
neuromuscular diseases arising in early childhood, including: spinal
muscular atrophy, Duchenne's muscular dystrophy, Charcot-Marie-
Tooth disease and spinal bulbar muscular atrophy. There are clearly
important implications both for the use of animal models to research
these diseases, and for the prognosis and treatment of patients.
Mouse models of a variety of neuromuscular disorders tend to
manifest during the ﬁrst post-natal month. The is certainly true of those
models mimicking pediatric neuromuscular disorders (Bowerman et al.,
2012; Le et al., 2005), but is also evident in spontaneous mutants with
peripheral neuropathies (Hedlund et al., 2010; Brown et al., 1995) and
models mimicking adult onset disorders (Schmalbruch et al., 1991; Xu
et al., 1993). Such models are commonly used to understand the mo-
lecular and structural events which occur during the disease time
course. Whilst this is clearly of great importance, it is also important to
consider how the evolving proteome impact upon the pathological
processes. Some pertinent examples of this arise from the SMA research
ﬁeld. This includes a marked diﬀerence in the severity in pathology
when Smn, the disease gene, is turned oﬀ in adulthood compared to in
neonates (Kariya et al., 2014) and a change in the severity and pattern
of selective vulnerability between SMA mouse models which manifest
at diﬀerent ages (Bowerman et al., 2012; Le et al., 2005; Murray et al.,
2008). The data we present here suggest that the diﬀerences in the
manifestation of neuromuscular pathology observed between these
mouse models is due to the evolving proteome occurring during the
time period. Indeed, several proteins which are known to impact upon
the pathological mechanisms implicated in neuromuscular pathology in
SMA and other motor neuron diseases were found to be altered during
the postnatal period. This includes proteins such as IGF2 which has
been shown to be an important modiﬁer in motor neuron disease
(Allodi et al., 2016; Hedlund et al., 2010).
It becomes increasing apparent that it will be of great importance to
understand how the timing of murine postnatal development relates to
human postnatal development. Mice clearly have a diﬀerent lifespan,
and are born with considerably diﬀerent motor abilities, and potentially
at a diﬀerent stage of neuromuscular maturity. The morphological
events occurring in the ﬁrst postnatal month in the mouse have been
extensively characterized, but the lack of available tissue makes it very
diﬃcult to know if and when these morphological changes occur into
humans. In mice, axons of the ventral ramus appear to grow out from
the spinal cord at around E12.5, reach the dorsal and ventral muscle
masses at around E13.5, and initial nerve muscle contacts are formed at
around E14.5 (Hurren et al., 2015). Acetylcholine receptor clusters are
not observed until around E14, becoming numerous at around E15
(Hurren et al., 2015). This suggests formation of neuromuscular con-
tacts occurs at around 60 to 70% of the way through gestation. Detail
on the equivalent process in human is inevitably more sparse, but
clusters of acetylcholine receptors and axon bundles have been ob-
served at around 10 gestational weeks, with plaque like endplate
structure visible at 14 gestational weeks (Martinez-Hernandez et al.,
2013). It has also been suggested that mono-innervated endplates could
be observed at 14 gestational weeks (Martinez-Hernandez et al., 2013).
Human NMJ formation therefore likely occurs at around 30% of the
way through gestation. Based on these ﬁgures, it would appear that the
initial formation of NMJs occurs at a comparably earlier time point in
humans than it does in mice. It is therefore tempting to assume that
humans are born with a comparatively more mature neuromuscular
system although clearly the details of human neuromuscular matura-
tion requires further investigation. However, the current proﬁling of
molecular events in mice will be of fundamental importance for future
comparison with human data.
Fig. 8. The AMP-kinase agonist AICAR accelerates
NMJ loss in P15 mice in an ex-vivo model of axonal
injury. (A) Representative confocal micrographs of
NMJs from deep lumbrical muscles isolated from P15
C57BL/6 J wildtype mice, after 24 h incubation ex-
vivo at 28 °C in either standard MPS CO3 ringer so-
lution or MPS CO3 ringer solution +2mM AICAR.
NMJs labelled with antibodies against neuroﬁlament
(NF; green) and synaptic vesicle protein 2 (SV2;
green) and alpha-bungarotoxin (BTX; red). Note in-
crease in the number of vacant endplates following
AICAR treatment. Scale bar= 30 μm (B) Bar chart
(Mean ± SEM) conﬁrms signiﬁcant decrease in the
percentage of fully occupied NMJs in AICAR-in-
cubated muscles compared to control. (n=4 mus-
cles/4 mice per group; *p < 0.05 by Mann-Whitney
U test). (For interpretation of the references to colour
in this ﬁgure legend, the reader is referred to the web
version of this article.)
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4.2. The role of mitochondria in WD
Functional annotation analysis of proteins exhibiting a steady up-
regulation over the P12-P24 period revealed a striking enrichment for
the processes of OXPHOS and associated mitochondrial functions, in
both the nerve and muscle. Strikingly, pathway analysis of proteomic
alterations occurring in both the nerve and the muscle further suggested
a conserved escalation in mitochondrial OXPHOS activity and redox
sensitivity pathways. Taken together, these ﬁndings invite considera-
tion of both how this might relate to the progressive acceleration in the
rate of WD, and how this information may impact upon our under-
standing of the mechanisms of synaptic and axonal degeneration.
The implication of mitochondria in the process of WD is certainly
not novel, although there is controversy as to the extent to which they
are required for the process of WD. Mitochondrial swelling during WD
has been noted in early ultra-structural studies of degenerating nerves
(Vial, 1958). It has been shown that over-expression of the mi-
tochondrially localized form of Nicotinamide mononucleotide adeny-
lyltransferase, Nmnat3, can protect axons from injury in both mouse
and drosophila models (Avery et al., 2012; Berger et al., 2005; Yahata
et al., 2009). The speciﬁcs of the involvement of mitochondria in WD
remain highly debated. It is clear that axon injury results in a reduction
in mitochondrial motility, and that this sudden reduction in mi-
tochondrial motility observed in wildtype axons following axotomy, is
markedly suppressed in Wlds axons (Avery et al., 2012). However it has
also been shown that there is also reduced mitochondrial motility in
axons from Sarm1 deﬁcient mice, in which the axons show a similar
Wlds like protection from axon degeneration (Summers et al., 2014).
This suggests that a reduction in mitochondrial motility is not necessary
for axon degeneration. A number of other cellular events which are
closely linked with mitochondria have been shown to have an im-
portant eﬀect upon axon degeneration. This includes energy depletion,
as evidenced by a reduction in NAD and ATP levels, a rise in calcium
levels and increased production of reactive oxygen species (Park et al.,
2013). Indeed it has been suggested that a key event in axon degen-
eration is the opening of the mitochondrial permeability transitioning
pore, which results in the observed swelling of the mitochondria and
the release of ROS and increase in calcium levels (Barrientos et al.,
2011; Villegas et al., 2014; Calixto et al., 2012). The speciﬁcs of the
relationships between the individual factors which have been shown to
inﬂuence axon degeneration remain to be deﬁned. However, from this
work, an important role for mitochondria is evident. For this reason,
our observed increase in mitochondrial protein expression is highly
likely to be associated with the acceleration in the rate of WD.
How then may the progressive increase in mitochondrial proteins
observed in neonatal mice lead to the progressive increase in the rate of
WD? The proteomic analysis points to a speciﬁc enrichment for proteins
pertaining to Complex I of the electron transport chain. Complex I has
been shown to be the rate limiting step in energy production at the
nerve terminal, a major source of protons for ATP synthesis and
therefore a major source of ROS production (Giachin et al., 2016;
Telford et al., 2009). ROS levels rise rapidly after axon injury and in-
hibition of ROS can delay axon degeneration (O'Donnell et al., 2013).
Indeed, here we show that the rise in ROS following injury in prevented
by application of a Complex I inhibitor, and this correlated with pro-
tection of the axon. This rise is ROS levels is not observed in Wlds mice,
thus presenting a possible mechanism of action (O'Donnell et al., 2013).
Furthermore, although the rise in ROS is still observed in Sarm1−/−
axons, they appear to be somehow resistant to oxidative damage caused
by ROS. This suggests that Sarm1 may mediate the damage caused by
ROS, and loss of Sarm1 leads to a delayed axon degeneration as the cell
is protected from damage caused by ROS (Summers et al., 2014). Given
that Complex I is a major source of ROS production (Giachin et al.,
2016; Telford et al., 2009), and inhibition of Complex I is protective to
axons, it seems reasonable to speculate that the increase in Complex I
activity between P12 and P24 can account for the acceleration in the
rate of WD over this same time period. Similarly, the lower level of
Complex I activity in neonatal nerve, results in a slower production of
ROS after nerve injury, and therefore a slower rate of WD. Previous
work has also shown that the opening of the MPTP induces a con-
formational change in Complex I, which leads to a rapid increase in
ROS production and release (Batandier et al., 2004). It is therefore
possible that the progressive increase in Complex I levels between P12
and P24 lead to increased ROS production following MPTP opening
during WD. In future work, it would be interesting to address the basal
and induced levels of ROS during axon degeneration in neonatal nerve.
5. Conclusions
Quantitative analysis revealed that the neuromuscular proteome
changes between the ages of P12 and P24, dynamically altering the
state of a broad range of molecular networks, most signiﬁcantly in those
involved in mitochondrial bioenergetics. Based on these ﬁndings, we
determined that pharmacologically up-regulating basal OXPHOS ac-
tivity at P12, an age characterized both in vivo and ex-vivo by a delay in
the rate of synaptic degeneration, results in signiﬁcantly increased
sensitivity of NMJ to axotomy. This suggests that basal levels of mi-
tochondrial OXPHOS activity may pre-condition the motor neuron to
degenerate more rapidly in the event of traumatic injury, perhaps
thereby facilitating axonal regeneration. We show than inhibition of
Complex I can prevent the axotomy related increase in ROS and that
this correlates with axon protection. Elucidating the mechanism by
which mitochondrial bioenergetics contributes to the injury-induced
molecular response should enhance understanding of motor neuron
degeneration. In a broader context, alterations in protein expression
across early postnatal development may inﬂuence the particular vul-
nerability of the motor neuron and skeletal muscle in neuromuscular
diseases of early childhood.
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.nbd.2019.104496.
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